Der­ma­vant en­gi­neers $160M deal to pay off Glax­o­SmithK­line mile­stones, gear up to launch pso­ri­a­sis cream

Der­ma­vant has nev­er been shy about its dreams to trans­form der­ma­tol­ogy with their top­i­cal cream. And the Roivant sub­sidiary has now found in­vestors just as en­thu­si­as­tic as they are.

Marathon As­set Man­age­ment, No­vaQue­st Cap­i­tal Man­age­ment and a third, un­named Boston-based in­vest­ment firm have agreed to shell out $160 mil­lion — if and on­ly if Der­ma­vant se­cures an ap­proval in plaque pso­ri­a­sis— in ex­change for a “sin­gle-dig­it per­cent­age rev­enue in­ter­est” of net tap­inarof sales, ac­cord­ing to the Roivant sub­sidiary. A big chunk of that mon­ey will go to Glax­o­SmithK­line as mile­stone pay­ments, while the rest will go to­ward com­mer­cial prepa­ra­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER